Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/12—Antidiarrhoeals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/08—Bronchodilators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/10—Drugs for disorders of the urinary system of the bladder
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/20—Hypnotics; Sedatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
  • A61P25/34—Tobacco-abuse
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
  • A61P27/06—Antiglaucoma agents or miotics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/10—Antioedematous agents; Diuretics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

• the present invention relates to azetidine derivatives, their preparation and their therapeutic application in the treatment or prevention of diseases involving CB 1 cannabinoid receptors.
• R represents a (C 1 -C 6 ) alkyl group, a halo (C 1 -C 6 ) alkyl group;
• R1 represents a hydrogen atom;
• R 2 represents a heterocycle group bonded by a carbon atom, a (C 1 -C 4 ) alkyl heterocycle group, these groups being optionally substituted by one or more atoms or groups chosen from a halogen, a hydroxy, oxo, cyano, NH 2 , C (O) NH 2 , a (C 1 -C 6 ) alkyl group, a halo (C 1 -C 6 ) alkyl group, a (C 1 -C 6 ) alkoxy group, a halo (C 1 -C 6 ) alkoxy group or a COO group ( Ci-C 6) alkyl;
• R3 and R4 independently of one another phenyl, optionally substituted by one or more atoms or groups selected from halogen, cyano, a (Ci-C 6) alkyl, halo (C 1 - C 6 ) alkyl, a (C 1 -C 6 ) alkoxy group or a halo (C 1 -C 6 ) alkoxy group;
• Y represents a hydrogen atom, a halogen, a cyano, a (C 1 -C 6 ) alkyl group, a halo (C 1 -C 6 ) alkyl group, a (C 1 -C 6 ) alkoxy group, a halo group (C 1 -C 6 ), C6) alkoxy or (C 1 -C 6 ) alkylS (O) p ;
• p is 0 to 2; in the form of a base or an acid addition salt.
• the compounds of formula (I) can comprise one or more asymmetric carbon atoms. They can therefore exist as enantiomers or diastereoisomers. These enantiomers, diastereoisomers, as well as their mixtures, including the racemic mixtures, form part of the invention.
• a first group of compounds consists of mixed compounds of diastereoisomers and enantiomers for which: R represents a methyl,
• R3 and R4 each represents a phenyl group substituted with a chlorine atom in the para position, Y represents a hydrogen atom or a halogen; R1 represents a hydrogen atom,
• R2 represents a heterocycle group bonded by a carbon atom or a heterocycle- (Cr) alkyl group and the heterocycle represents a tetrahydrothiophene, piperidine, tetrahydrothiopyran, azetidine, pyrrolidine, imidazolidine which are optionally substituted by one or more groups (C r C 6 ) alkyl, COO (C r C 6 ) alkyl or oxo in the form of a base or an acid addition salt.
• a halogen a fluorine, a chlorine, a bromine or an iodine
• a (C 1 -C 6) alkyl group an aliphatic group comprising from 1 to 6 saturated, cyclic, branched or linear carbon atoms which may optionally be substituted by one or more linear, branched or cyclic (C 1 -C 6) alkyl groups.
• halo (C 1 -C 6 ) alkyl group a (C 1 -C 6 ) alkyl group in which one or more hydrogen atoms have been substituted by a halogen atom.
• - hydroxy (C r C6) alkyl a (Ci-C 6) alkyl wherein one or more hydrogens have been substituted with one or more hydroxy group (Ci-C 6) alkoxy, a group (C -C 6) alkyl-O- where the (.
• C f C ⁇ alkyl is as defined above, halo (Ci-C 6) alkoxy: halo (C r C 6) alkyl-O- wherein the group halo (d-C 6 ) alkyl is as previously defined, a heterocycle group is a saturated or partially saturated monocyclic group having from 4 to 6 atoms, including 1 to 3 heteroatoms chosen from O, N, S, provided that when there is an oxygen present there is at least one other heteroatom selected from N, S.
• the N or S heteroatoms may be present in the oxidized form that is to say NO or S (O) or SO 2 .
• a heterocycle group (Ci-C 4) alkyl group is an alkyl group substituted by such a heterocyclic ring as defined above.
• the compounds of formula (I) may exist in the form of bases or salts. Such addition salts are part of the invention.
• salts can be prepared with pharmaceutically acceptable acids, but the salts of other acids that are useful, for example, for the purification or the isolation of the compounds of formula (I) are also part of the invention.
• the compounds of formula (I) may also exist in the form of hydrates or solvates, namely in the form of associations or combinations with one or more water molecules or with a solvent. Such hydrates and solvates are also part of the invention.
• the compounds of formula (I) may also exist in the form of tautomers and are also part of the invention.
• the present invention also relates to the use of the compounds of the invention of formula (I) for the preparation of a medicament for the treatment or prevention of diseases in which the CB1 receptor is involved.
• the subject of the present invention is also the use of the compounds of the invention of formula (I) for the preparation of a medicament for the treatment or the prevention of psychiatric disorders, addiction and weaning to a substance, weaning smoking, cognitive disorders and attention and acute and chronic neurodegenerative diseases; metabolism, appetite disorders, appetite disorders, obesity, diabetes (type I and / or H), metabolic syndrome, dyslipidemia, sleep apnea; pain, neuropathic pain, neuropathic pain induced by anticancer drugs; gastrointestinal disorders, vomiting, ulcer, diarrhea, bladder and urinary disorders, endocrine disorders, cardio-vascular disorders, hypotension, hemorrhagic shock, septic shock, liver diseases, chronic cirrhosis of the liver, fibrosis, non-alcoholic steatohepatitis (NASH), steatohepatitis and hepatic steatosis, regardless of the etiology of these conditions (alcohol, drug, chemical, autoimmune disease, obesity, diabetes, congenital metabolic
• the mesylation of compound 1 to derivative 2 can be carried out according to methods known to those skilled in the art or described in TW GREENE, Protective Group in Organic Synthesis, fourth edition. This reaction will be carried out in a chlorinated solvent such as dichloromethane in the presence of a base such as pyridine and a mesylate derivative such as mesyl chloride at a temperature between -10 ° C. and 40 ° C.
• the derivatives 1 are commercial or synthesized, according to the methods known to those skilled in the art, from the appropriate commercial precursors, R "represents a protecting group of the OH function of the acid.
• the derivative 4 is accessible by reaction of mesylate 2 with azetidine 3.
• This step is preferably carried out under an inert atmosphere, in an inert solvent such as 4-methyl-2-pentanone in the presence of a base. mineral such as potassium carbonate at the reflux of the reaction mixture.
• an inert solvent such as 4-methyl-2-pentanone
• mineral such as potassium carbonate
• ester 4 to acid 5 is carried out according to the methods known to those skilled in the art and, more specifically, in a mixture of polar solvents such as tetrahydrofuran and water in the presence of a base such as lithium hydroxide hydrated at a temperature in the region of 20 ° C.
• polar solvents such as tetrahydrofuran
• base such as lithium hydroxide hydrated at a temperature in the region of 20 ° C.
• T The formation of the compounds of formula (T) can be carried out by reaction between the acid 5 and an amino derivative 6:
• a polar solvent such as tetrahydrofuran or a chlorinated solvent such as dichloromethane
• a base such as a trialkylamine (triethylamine)
• a coupling agent such as 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride or supported carbodiimide, in the presence or absence of an additive (1-hydroxybenzotriazole, for example
• a polar solvent such as tetrahydrofuran or a chlorinated solvent such as dichloromethane
• a base such as trialkylamine (triethylamine or diisopropylethylamine, for example)
• a favoring agent such as triethylamine or diisopropylethylamine, for example
• peptide synthesis via the formation of a mixed anhydride such as isobutylchloroformate, and at a temperature of between -50 ° C. and the boiling point of the solvent.
• the derivatives 6 are commercially available or synthesized, according to the methods known to those skilled in the art, from the appropriate commercial precursors.
• Compounds of formula (T) may be pre-purified by reaction of an acid derivative with an amine derivative 6 are reacted in an inert solvent; in the presence of a coupling agent and optionally of an additive avoiding racemization, the product is optionally deprotected and then the product is isolated and optionally converted into an acid addition salt.
• the compounds of formula (T) can be purified by the usual known methods, for example by crystallization, chromatography or extraction.
• the enantiomers of the compounds of formula (T) can be obtained by resolution of the racemates, for example by chromatography on a chiral column according to PBRKLE WH et al., Asymmetric Synthesis, vol. I 5 Academic Press (1983) or by formation of salts or by synthesis from chiral precursors.
• the diastereoisomers can be prepared according to known conventional methods (crystallization, chromatography or from chiral precursors).
• the present invention also relates to the process for preparing the intermediates.
• Example 1 3- [ ⁇ 1- [Bis (4-chlorophenyl) methyl] azetidin-3-yl ⁇ (methylsulfonyl) amino] -N- [3- (2-oxopyrrolidin-1-yl) propyl] benzamide (Compound No. 1) 0.5 g of 3 - [ ⁇ 1- [bis (4-chlorophenyl) methyl] azetidin-3-yl ⁇ (methylsulfonyl) amino] benzoic acid, 10 cm 3 of dichloromethane and 0.115 cm 3 of - (3-aminopropyl) pyrrolidin-2-one are stirred at a temperature close to 20 ° C.
• the reaction medium After stirring overnight at a temperature in the region of 20 ° C., the reaction medium is diluted with 25 cm 3 of water and 20 cm 3 of water. dichloromethane. After decantation, the aqueous phase is extracted twice with 20 cm 3 of dichloromethane. The combined organic phases are dried, filtered and then concentrated to dryness under reduced pressure.
• the crude reaction product obtained is purified by flash chromatography on a column of 30 g of silica (elution gradient: acetonitrile / methanol: up to 80/20). After concentration of the fractions under reduced pressure, a white meringue is obtained which is solubilized in a minimum of dichloromethane. To this solution is added heptane until a disorder.
• Example 8 3 - [ ⁇ 1- [bis (4-chlorophenyl) methyl] azetidin-3-yl ⁇ (methylsulfonyl) amino] -
• reaction medium After stirring for 19 hours at a temperature in the region of 20 ° C., the reaction medium is cooled to a temperature close to -20 ° C. before hydrolysis with 15 cm 3 of water. The medium is then stirred for 1 hour at a temperature in the region of 20 ° C. and then extracted 3 times with 20 cm 3 of ethyl acetate. The organic phases are combined, dried over magnesium sulfate and then filtered before concentration to dryness.
• Example 10 (-) - 3 - [ ⁇ 1- [bis (4-chlorophenyl) methyl] azetidin-3-yl ⁇ (methylsulfonyl) amino] -5-fluoro-N- [2-oxopyrrolidin-3-yl] benzamide (Compound No. 16) The levorotatory enantiomer is elected in second position.
• Table 1 which follows illustrates the chemical structures (I) and the physical properties of some examples of compounds according to the invention.
• Table 1 which follows illustrates the chemical structures (I) and the physical properties of some examples of compounds according to the invention.
• Table 1 which follows illustrates the chemical structures (I) and the physical properties of some examples of compounds according to the invention.
• Table 1 which follows illustrates the chemical structures (I) and the physical properties of some examples of compounds according to the invention.
• Table 1 which follows illustrates the chemical structures (I) and the physical properties of some examples of compounds according to the invention.
• R3 and R4 each represent a phenyl group substituted with a chlorine atom in the para position
• the compounds according to the invention have been the subject of pharmacological tests making it possible to determine the activity with respect to human CB1 cannabinoid receptors.
• the effectiveness of the compounds of formula (I) was determined in a functional test measuring CB1 cannabinoid receptor activity (intracellular cyclic AMP test).
• the detection test of intracellular cyclic AMP in U373MG cells naturally expressing the human CB1 receptor was performed as described in the reference: Bouaboula et al., 1995, J. Biol. Chem. 270: 13973-13980.
• CisBio's hTRF cAMP Dynamic Kit was used for quantification of intracellular cyclic AMP.
• the IC 50 values are between 0.001 ⁇ M and 1 ⁇ M.
• Compounds Nos . 9, 14, 16, 2 have shown IC 50s respectively 130, 9, 7,
• CD1 male mice received the test product orally 30 minutes or 2 hours prior to administration of the racemic CP55,940 agonist (1RS, 3RS, 4RS-3- [hydroxy-2- (1,1- dimethylheptyl) phenyl] -4- (3-hydroxypropyl) cyclohexan-1-ol) (0.15 mg / kg ip in 10% cremophore).
• the animals receive a bolus of coal in.
• the animals are euthanized (CO 2 / O 2 ) and the intestine is dissected. The progression of the bolus of charcoal in the intestine is expressed as a percentage of the total length of the intestine.
• the compounds of the invention of formula (I) are CB1 cannabinoid receptor antagonists in vitro and in vivo. Some compounds are active in vivo on both the hypothermia and transit test, and some compounds show dissociated activities between the hypothermia and transit test.
• the compounds according to the invention can be used in the treatment or prevention of diseases involving CB1 cannabinoid receptors. These compounds have a peripheral activity dissociated from the central activity.
• the compounds of formula (I) are useful as psychotropic drugs, especially for the treatment of psychiatric disorders including anxiety, depression, mood disorders, insomnia, delusional disorders , obsessive-compulsive disorder, psychosis in general, schizophrenia, attention deficit hyperactivity disorder (ADHD) in hyperkinetic children (BDM), and the treatment of disorders related to the use of psychotropic substances , in particular in the case of an abuse of substance and / or substance dependence, including alcohol dependence and nicotine addiction and withdrawal disorders.
• the compounds of formula (I) according to the invention can be used as medicaments for the treatment of migraine, stress, psychosomatic diseases, panic attacks, epilepsy, movement disorders , especially dyskinesias or Parkinson's disease, tremors and dystonia.
• the compounds of formula (I) according to the invention can be used as medicaments for skin cancer and skin protection.
• the compounds of formula (I) according to the invention can also be used as medicaments in the treatment of memory disorders, cognitive disorders, in particular in the treatment of cognitive disorders related to senile dementia, to Alzheimer's disease, to schizophrenia and neurodegenerative diseases, as well as in the treatment of attention deficit or alertness disorders.
• the compounds of formula (F) may be useful as neuroprotective agents, in the treatment of ischemia, head trauma and the treatment of neurodegenerative diseases: including Huntington's chorea, Tourrette's syndrome.
• the compounds of formula (I) according to the invention can be used as medicaments in the treatment of pain: neuropathic pain, peripheral acute pain, chronic pain and pain of inflammatory origin.
• the compounds of formula (I) according to the invention can be used as medicaments in the treatment of appetite disorders, palatability (for sugars, carbohydrates, drugs, alcohols or any appetizing substance) and / or conduits. for the treatment of bulimia as well as for the treatment of type II diabetes or non-insulin-dependent diabetes and for the treatment of dyslipidemia, metabolic syndrome.
• the compounds of formula (I) according to the invention are useful in the treatment of obesity and the risks associated with obesity, in particular cardiovascular risks.
• the compounds of formula (I) according to the invention can be used as medicaments in the treatment of gastrointestinal disorders, diarrheal disorders, ulcers, vomiting, bladder and urinary disorders, endocrine, cardiovascular disorders, hypotension, hemorrhagic shock, septic shock, cirrhosis, hepatic fibrosis, steatohepatitis and hepatic steatosis, regardless of the etiology of these conditions: especially viruses, alcohol, drugs, chemicals, autoimmune diseases, obesity, diabetes, congenital metabolic disease, (hemochromatosis, alpha-1 antitrypsin deficiency, Wilson's disease, etc.), chronic cirrhosis of the liver, Fibrosis, non-alcoholic steatohepatitis (NASH), asthma, chronic obstructive pulmonary disease, Raynaud's syndrome, glaucoma, fertility disorders, inflammatory phenomena, inflammatory diseases, diseases of the immune system, particularly autoimmune and neuroinflammatory such as rheumatoid
• the present invention relates to pharmaceutical compositions comprising, as active principle, a compound according to the invention.
• These pharmaceutical compositions contain an effective dose of at least one compound according to the invention, or a pharmaceutically acceptable salt, of said compound, as well as at least one pharmaceutically acceptable excipient.
• Said excipients are chosen according to the pharmaceutical form and the desired mode of administration, from the usual excipients which are known to those skilled in the art.
• compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intratracheal, intranasal, transdermal or rectal administration the active ingredient of formula (I) above, or its salt, can be administered in unit dosage form, in admixture with conventional pharmaceutical excipients for the treatment of the disorders or diseases mentioned above.
• Suitable unit dosage forms include oral forms such as tablets, soft or hard capsules, powders, granules and oral solutions or suspensions, sublingual, oral, intratracheal, intraocular, intranasal forms of administration. by inhalation, topical, transdermal, subcutaneous, intramuscular or intravenous administration forms, rectal administration forms and implants.
• the compounds according to the invention can be used in creams, gels, ointments or lotions.
• a unitary form of administration of a compound according to the invention in tablet form may comprise the following components:
• the dosage appropriate to each patient is determined by the physician according to the mode of administration, the weight and the response of said patient.
• the present invention also relates to a method of treatment of the pathologies indicated above which comprises the administration to a patient of an effective dose of a compound according to the invention, or of a pharmaceutically acceptable salt thereof.

Applications Claiming Priority (2)

Publications (1)

Family

ID=40352477

Family Applications (1)

Country Status (16)

Families Citing this family (2)

Family Cites Families (1)

• 2008
  • 2008-08-14 FR FR0804596A patent/FR2934996B1/fr not_active Expired - Fee Related
• 2009
  • 2009-08-13 JP JP2011522539A patent/JP2011530576A/ja not_active Withdrawn
  • 2009-08-13 AU AU2009281058A patent/AU2009281058A1/en not_active Abandoned
  • 2009-08-13 BR BRPI0917944A patent/BRPI0917944A2/pt not_active Application Discontinuation
  • 2009-08-13 KR KR1020117005732A patent/KR20110042114A/ko not_active Application Discontinuation
  • 2009-08-13 MX MX2011001669A patent/MX2011001669A/es not_active Application Discontinuation
  • 2009-08-13 EP EP09736249A patent/EP2313392A1/de not_active Withdrawn
  • 2009-08-13 AR ARP090103132A patent/AR073044A1/es unknown
  • 2009-08-13 TW TW098127314A patent/TW201022248A/zh unknown
  • 2009-08-13 RU RU2011109204/04A patent/RU2011109204A/ru not_active Application Discontinuation
  • 2009-08-13 WO PCT/FR2009/001004 patent/WO2010018329A1/fr active Application Filing
  • 2009-08-13 US US13/058,885 patent/US20110183961A1/en not_active Abandoned
  • 2009-08-13 CN CN2009801408180A patent/CN102186838A/zh active Pending
  • 2009-08-13 CA CA2734082A patent/CA2734082A1/fr not_active Abandoned
  • 2009-08-14 UY UY0001032050A patent/UY32050A/es not_active Application Discontinuation
• 2011
  • 2011-02-13 IL IL211209A patent/IL211209A0/en unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events